Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  dasatinib
Find trials that include:  Any drugs shown
Results 1-25 of 30 for your search:
Start Over
Risk-Directed Therapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and under
Trial IDs: TOTXVI, NCI-2011-01254, NCT00549848
Dasatinib and Decitabine in Treating Patients with Accelerated or Blastic Phase Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0333, NCI-2012-00014, CA180357, NCT01498445
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PRI-724-201, NCI-2012-01153, NCT01606579
Dasatinib in Treating Patients with Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated with Autologous Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-180-381, NCI-2012-00767, 1203010693, 2011-203, NCT01609816
Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-180-384, NCI-2012-00773, 2011-204, NCT01643603
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
Dasatinib, Cytarabine, and Idarubicin Hydrochloride in Treating Patients with High-Risk Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 12393, NCI-2013-01141, 106482, NCT01876953
Dasatinib in Treating Patients with Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2607, NCI-2009-00532, CDR0000598300, ECOG-E2607, NCT00700882
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TRIO-TORI PA-01, NCI-2010-02190, NCT01234935
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BMS CA180-280, NCI-2011-03136, HEM 10010-L, OHSU-6146, NCT01441882
Cetuximab and Dasatinib in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer Previously Treated With Cetuximab and Chemoradiation Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 08-034, NCI-2011-03734, CA180264, NCT01488318
Open Label, Randomized Phase 2b Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who do Not Have Favorable Imatinib Response (DASCERN)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA180-399, NCI-2012-02781, 2011-006181-41, NCT01593254
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: 7195, NCI-2012-01084, CA180-392, NCT01620216
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA180-406, NCI-2013-01675, 2012-001421-27, NCT01850004
Vaccine Therapy and Dasatinib in Treating Patients With Stage IIIB-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: 12-048, NCI-2013-01905, NCT01876212
Intensive Combination Chemotherapy and Liposomal Cytarabine in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: UCSD 130934, NCI-2014-02017, 130934, NCT02043587
Dasatinib in Treating Patients with Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-0283, NCI-2014-00209, NCT02059265
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: S1318, NCI-2014-01047, SWOG-S1318, NCT02143414
Dasatinib in Treating Patients with Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery and Has an IDH Mutation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00938, CA180-603, NCT02428855
Dasatinib and Tretinoin in Treating Patients With Acute Myeloid Leukemia
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-160, NCI-2011-02494, NCT00892190
Dasatinib and Ipilimumab in Treating Patients with Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-083, NCI-2012-01165, CDR0000737378, 9172, NCT01643278
Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: SJHG12, NCI-2012-01240, NCT01644773
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients with Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: 18 and ove
Trial IDs: GI 1173, NCI-2012-01290, CDR0000738551, NCI-2012-01175, VICCGI1173, 9043, NCT01660971
Dasatinib and Crizotinib in Treating Patients with Advanced Malignancies
Phase: Phase I
Type: Treatment
Age: 16 and over
Trial IDs: 2012-0721, NCI-2013-00071, NCT01744652
Afatinib Dimaleate and Dasatinib in Treating Patients with Advanced or Recurrent Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC 17176, NCI-2014-00003, 1200.166, BI 1200.166, BMS CA180-379, CA180-379, NCT01999985
Start Over